Users

Rosiglitazone

Rosiglitazone

ATC Code: A10BG02

Warning

Patients may be asking about a New York Times report that some FDA staff are recommending that rosiglitazone, sold in the U.S. as Avandia to treat type 2 diabetes, "be removed from the market." The story, based on "internal FDA reports" and a Senate Committee on Finance staff report, says that "hundreds of people taking Avandia ... needlessly suffer heart attacks and heart failure each month." The committee report concludes: "The totality of evidence suggests that [GlaxoSmithKline] was aware of the possible cardiac risks associated with Avandia years before such evidence became public." In separate press releases, GlaxoSmithKline disputes the conclusions, both of the Times article and the Senate report, saying that "the scientific evidence simply does not establish that Avandia increases ischemic cardiovascular risk or causes myocardial ischemic events."

Evidence

Good

Reference